Blab News
FDA Approves First Generic Xofluza for Flu Treatment and Prophylaxis
On June 17, 2026, the U.S. Food and Drug Administration (FDA) approved the first generic version of Xofluza, the brand‑name antiviral baloxavir marboxil, for use in patients five years of age and older. The approval, granted to Norwich Pharmaceuticals, Inc., comes in time for the 2026‑2027 flu season and represents the first single‑dose treatment and post‑exposure prophylaxis option available in generic form.
"Today’s approval marks a meaningful milestone for the treatment of influenza," said Iilun Murphy, M.D., Director of the Office of Generic Drugs in FDA’s Center for Drug Evaluation and Research. "Expanding patient access to drugs and improving their ease of use are critical public health imperatives, particularly given that influenza alone accounts for millions of illnesses in the U.S. each year."
The generic baloxavir marboxil tablets are intended for two indications. First, they treat acute uncomplicated influenza in patients who have been symptomatic for no more than 48 hours and who are otherwise healthy or at high risk for complications. Second, they provide post‑exposure prophylaxis for patients who have come into contact with an individual with influenza. The drug is contraindicated in patients with a known history of hypersensitivity to baloxavir marboxil or any of its ingredients, and the FDA notes a warning about increased incidence of treatment‑emergent resistance in patients younger than five years.
Common side effects reported for baloxavir marboxil include diarrhea, bronchitis, nausea, sinusitis, and headaches. Healthcare providers are advised to review the full prescribing information for detailed safety and dosing guidance.
The approval follows the FDA’s Drug Competition Action Plan, which seeks to increase the availability of generic drugs and foster market competition. In the United States, nine out of ten prescriptions filled are for generic drugs, a statistic that underscores the importance of expanding generic options for cost‑effective care.
Baloxavir marboxil was first approved by the FDA in 2018 for the treatment of influenza A and B. The medication works by inhibiting the influenza virus’s cap‑dependent endonuclease, an enzyme essential for viral replication. Clinical studies have shown that the drug can reduce the duration of flu symptoms by about one to two days in some patients.
The generic approval was achieved through the Abbreviated New Drug Application (ANDA) pathway, which allows manufacturers to demonstrate bioequivalence to the brand‑name product without repeating the full clinical trial program. Norwich Pharmaceuticals submitted the ANDA to the FDA’s Center for Drug Evaluation and Research, Office of Generic Drugs, and the agency approved the application after confirming that the generic tablets meet the same quality, safety, and efficacy standards as the original Xofluza.
The Trump Administration has emphasized the importance of lowering prescription drug prices, and the approval of a generic Xofluza aligns with that policy. The FDA’s decision is expected to broaden access to a single‑dose antiviral that can be taken at home, potentially reducing the burden on healthcare facilities during peak flu periods.
Public health officials anticipate that the generic availability will help more patients receive timely treatment, especially in communities with limited access to specialty pharmacies. The FDA’s announcement also highlights the agency’s ongoing role in safeguarding public health by ensuring that effective medications remain affordable.
The generic Xofluza will be available for prescription through pharmacies nationwide. Patients and providers can expect the drug to be listed in the FDA’s Orange Book as a bioequivalent product to the original brand. The approval does not alter the existing patent status of the brand‑name drug, but it does introduce a lower‑priced alternative that may influence prescribing patterns.
As the 2026‑2027 flu season approaches, clinicians will monitor the uptake of the generic formulation and assess its impact on treatment outcomes. The FDA will continue to oversee post‑marketing surveillance to detect any emerging safety signals. The approval represents a significant step toward expanding affordable antiviral options for the American public.
"Today’s approval marks a meaningful milestone for the treatment of influenza," said Iilun Murphy, M.D., Director of the Office of Generic Drugs in FDA’s Center for Drug Evaluation and Research. "Expanding patient access to drugs and improving their ease of use are critical public health imperatives, particularly given that influenza alone accounts for millions of illnesses in the U.S. each year."
The generic baloxavir marboxil tablets are intended for two indications. First, they treat acute uncomplicated influenza in patients who have been symptomatic for no more than 48 hours and who are otherwise healthy or at high risk for complications. Second, they provide post‑exposure prophylaxis for patients who have come into contact with an individual with influenza. The drug is contraindicated in patients with a known history of hypersensitivity to baloxavir marboxil or any of its ingredients, and the FDA notes a warning about increased incidence of treatment‑emergent resistance in patients younger than five years.
Common side effects reported for baloxavir marboxil include diarrhea, bronchitis, nausea, sinusitis, and headaches. Healthcare providers are advised to review the full prescribing information for detailed safety and dosing guidance.
The approval follows the FDA’s Drug Competition Action Plan, which seeks to increase the availability of generic drugs and foster market competition. In the United States, nine out of ten prescriptions filled are for generic drugs, a statistic that underscores the importance of expanding generic options for cost‑effective care.
Baloxavir marboxil was first approved by the FDA in 2018 for the treatment of influenza A and B. The medication works by inhibiting the influenza virus’s cap‑dependent endonuclease, an enzyme essential for viral replication. Clinical studies have shown that the drug can reduce the duration of flu symptoms by about one to two days in some patients.
The generic approval was achieved through the Abbreviated New Drug Application (ANDA) pathway, which allows manufacturers to demonstrate bioequivalence to the brand‑name product without repeating the full clinical trial program. Norwich Pharmaceuticals submitted the ANDA to the FDA’s Center for Drug Evaluation and Research, Office of Generic Drugs, and the agency approved the application after confirming that the generic tablets meet the same quality, safety, and efficacy standards as the original Xofluza.
The Trump Administration has emphasized the importance of lowering prescription drug prices, and the approval of a generic Xofluza aligns with that policy. The FDA’s decision is expected to broaden access to a single‑dose antiviral that can be taken at home, potentially reducing the burden on healthcare facilities during peak flu periods.
Public health officials anticipate that the generic availability will help more patients receive timely treatment, especially in communities with limited access to specialty pharmacies. The FDA’s announcement also highlights the agency’s ongoing role in safeguarding public health by ensuring that effective medications remain affordable.
The generic Xofluza will be available for prescription through pharmacies nationwide. Patients and providers can expect the drug to be listed in the FDA’s Orange Book as a bioequivalent product to the original brand. The approval does not alter the existing patent status of the brand‑name drug, but it does introduce a lower‑priced alternative that may influence prescribing patterns.
As the 2026‑2027 flu season approaches, clinicians will monitor the uptake of the generic formulation and assess its impact on treatment outcomes. The FDA will continue to oversee post‑marketing surveillance to detect any emerging safety signals. The approval represents a significant step toward expanding affordable antiviral options for the American public.
